STRIDES PHARMA SCIENCE share price has zoomed 4% and is presently trading at Rs 944.0.
Meanwhile, the BSE HEALTHCARE index is at 38,800.4 .
Among the top gainers in the BSE HEALTHCARE index today are ALEMBIC PHARMA (up 4.2%) and GSK Pharma (up 3.5%).
MAX HEALTHCARE INSTITUTE (down 1.2%) and IPCA Labs (down 0.8%) are among the top losers today.
Over the last one year, STRIDES PHARMA SCIENCE has moved up from Rs 443.1 to Rs 944.0, registering a gain of Rs 500.9 (up 113.0%).
On the other hand, the BSE HEALTHCARE index has moved up from 26,286.8 to 38,800.4, registering a gain of 47.6% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Glenmark Pharma (up 108.4%), Cadila Healthcare (up 99.9%) and Lupin (up 94.8%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 80,809.7 (up 0.2%).
The top gainers among the BSE Sensex today are Tata Steel (up 1.2%) and M&M (up 1.2%). The most traded stocks in the BSE Sensex are Tata Steel and NTPC.
In the meantime, NSE Nifty is at 24,636.1 (up 0.2%). BPCL and Coal India are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,393.9 to 80,809.7, registering a gain of 15,415.8 points (up 23.6%).
STRIDES PHARMA SCIENCE net profit grew 119.9% YoY to Rs 590 million for the quarter ended March 2024, compared to a profit of Rs 268 million a year ago. Net sales rose 9.9% to Rs 10,840 million during the period as against Rs 9,864 million in January-March 2023.
For the year ended March 2023, STRIDES PHARMA SCIENCE reported 51.3% increase in net profit to Rs -2,309 million compared to net loss of Rs 4,743 million during FY22. Revenue of the company grew 20.1% to Rs 36,884 million during FY23.
The current Price to earnings ratio of STRIDES PHARMA SCIENCE, based on rolling 12 month earnings, stands at 319.0.
Equitymaster requests your view! Post a comment on "STRIDES PHARMA SCIENCE Gains 4%; BSE HEALTHCARE Index Up 0.0%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!